Anti human CI 135 (FLT3) chimeric antigen receptor T cell therapy - Hrain Biotechnology
Alternative Names: CI-135; FLT3 CAR-TLatest Information Update: 10 Feb 2025
At a glance
- Originator HRAIN Biotechnology
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase 0 Acute myeloid leukaemia
Most Recent Events
- 26 Jan 2022 Phase-0 for Acute myeloid leukaemia (Second-line therapy or greater) in China (Parenteral) (NCT06760260)